[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Yaşar Bayındır, MD\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":132},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,43,76,102],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100633629","hbv-reactivation-in-immunocompromised-patients-reant-study-100633629",false,"NCT07529171","HBV Reactivation in Immunocompromised Patients (REANT STUDY)","Management and Monitoring of HBV Reactivation in Immunocompromised Patients in Turkey (REANT STUDY)","Inclusion Criteria:\n\n* Aged 18 years or older\n* Positive for Anti-HBc IgG\n* Must be candidate for immunosuppressive therapy.\n\nExclusion Criteria:\n\n* Voluntary Withdrawal\n* Failure to attend follow-up visits","ALL","18 Years","80 Years",{"count":20,"type":21},490,"ESTIMATED","48 Months","OBSERVATIONAL","Background\u002FObjective: Comorbidities represent a critical risk factor in the prognosis of patients receiving immunosuppressive therapy. For patients with anti-HBc IgG positivity requiring Hepatitis B virus (HBV) prophylaxis, the long-term physiological impact of oral antivirals remains a concern. This study aims to prospectively monitor bone, renal, and metabolic dysfunctions associated with oral antiviral use and other systemic risk factors over a long-term period.\n\nMethods: The REANT Cohort is designed as a 4-year, multicenter prospective study. The cohort will consist of patients initiated on HBV prophylaxis due to immunosuppressive treatment. Participants will undergo regular longitudinal assessments to evaluate bone mineral density, renal filtration and tubular functions, and metabolic profiles. The interplay between antiviral therapy, baseline comorbidities, and long-term organ dysfunction will be analyzed.\n\nConclusion: The findings from the REANT Cohort are expected to provide robust evidence regarding the safety of long-term HBV prophylaxis and assist in the development of monitoring guidelines for immunosuppressed patients with latent HBV infection.",[26],"HBV",[28,29],"HBV reactivation","Immunosuppressive therapy","RECRUITING","2026-08-01",{"date":33,"type":34},"2026-08-04","ACTUAL",{"date":36,"type":34},"2026-03-09",{"date":38,"type":21},"2029-12-31",{"name":40,"class":41},"Yaşar Bayındır, MD","OTHER",16,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":51,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":52,"targetDuration":54,"studyType":23,"phases":4,"briefSummary":55,"conditions":56,"keywords":60,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},"100649650","metabolic-liver-disease-in-newly-diagnosed-people-living-with-hiv-mashiv-tr-100649650","NCT07737340","Metabolic Liver Disease in Newly Diagnosed People Living With HIV (MASHIV-TR)","Metabolic Liver Disease in Newly Diagnosed People Living With HIV: MASHIV-TR Cohort (MASHIV-TR)","MASHIV-TR","Inclusion Criteria (For the Patient Group \u002F Newly Diagnosed HIV+):\n\n* Citizens of the Republic of Türkiye\n* Adults (≥ 18 years of age)\n* Confirmed Anti-HIV positive (Newly diagnosed)\n* Patients who are initiating Antiretroviral Therapy (ART)\n\nInclusion Criteria (For the Healthy Control Group \u002F HIV-):\n\n* Citizens of the Republic of Türkiye\n* Adults (≥ 18 years of age)\n* Confirmed Anti-HIV negative\n\nExclusion Criteria:\n\n* There are no specified exclusion criteria for this study.",true,{"count":53,"type":21},411,"60 Months","This study aims to identify the risk factors that lead to the development of metabolic liver disease in people who have been newly diagnosed with HIV. The research will take place across 9 centers in Türkiye and plans to include 250 newly diagnosed individuals with HIV, alongside 161 healthy individuals without HIV as a control group.\n\nParticipants will have their liver health checked when they first join the study (baseline) and then once a year for up to 5 years (at 12, 24, 36, 48, and 60 months). The main goal of these visits is to monitor their metabolic health and understand who is at risk of developing a fatty liver condition known as MASLD (Metabolic dysfunction-Associated Steatotic Liver Disease).\n\nDuring each visit, the research team will collect information about the participants' general health, including their height, weight, medical and family history, lifestyle habits, and sleep patterns. They will also record any medications being taken, including HIV treatments. To thoroughly check liver health, researchers will use routine blood tests (measuring things like cholesterol, blood sugar, and kidney function) and painless, non-invasive imaging tests, such as ultrasounds and FibroScans, to measure liver fat and stiffness.",[57,58,59],"HIV Infections","Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) & Steatohepatitis (MASH)","Fatty Liver",[61,62,63,64,65,66],"HIV","Newly Diagnosed HIV Infection","Antiretroviral Therapy (ART)","Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD)","Metabolic Dysfunction-Associated Steatohepatitis (MASH)","Metabolic Syndrome","2026-07-29",{"date":69,"type":34},"2026-07-30",{"date":71,"type":34},"2024-06-01",{"date":73,"type":21},"2029-05-31",{"name":40,"class":41},11,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":83,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":85,"conditions":86,"keywords":88,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},"100628268","entecavir-resistance-associated-mutations-in-chronic-hbv-patients-in-turkey-stream-study-100628268","NCT07459426","Entecavir Resistance-Associated Mutations in Chronic HBV Patients in Turkey (STREAM Study)","Sequencing-Based Tracking of Entecavir Resistance-Associated Mutations in Chronic Hepatitis B Patients: A Multicenter Observational Study (STREAM)","Inclusion Criteria:\n\n* Age ≥18 years\n* HBsAg positive\n* Group 1: Either treatment-naïve participants with HBV DNA\\>2000 IU\u002Fml\n* Group 2: Prior lamivudine therapy ≥6 months with switch to ADVor TDF or TAF\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* Prior entecavir exposure\n* Prior telbivudine exposure\n* Age \\\u003C18 years\n* Inability to provide informed consent Note: Previous adefovir or (pegylated) interferon use is not an exclusion criterion.\n\nPatients with insufficient sample volume or inadequate DNA quality for sequencing will be excluded from final analysis.",{"count":84,"type":21},700,"Chronic hepatitis B is a long-term viral infection that affects millions of people worldwide. Patients usually require lifelong antiviral treatment to control the virus and prevent liver damage.\n\nSome older antiviral medications, such as lamivudine, can lead to the development of viral resistance. This means the virus changes in a way that makes certain treatments less effective. Even though newer drugs like entecavir are stronger and more resistant to these changes, previous exposure to lamivudine may increase the risk of developing additional resistance mutations.\n\nBy analyzing viral genetic material from blood samples using advanced sequencing technology, this research will help improve understanding of antiviral resistance patterns in patients with chronic hepatitis B in Turkey and may support better treatment decisions in the future.",[87],"Hepatitis B, Chronic",[89,90,91,92],"Chronic hepatitis B","Lamivudine","Entecavir","Antiviral resistance","NOT_YET_RECRUITING","2026-03-05",{"date":36,"type":34},{"date":97,"type":21},"2026-03-15",{"date":99,"type":21},"2027-03-15",{"name":40,"class":41},1,{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":51,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":110,"targetDuration":112,"studyType":23,"phases":4,"briefSummary":113,"conditions":114,"keywords":120,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":131},"100535188","find-hdv-and-determine-its-status-in-turkey-100535188","NCT06248580","Find HDV and Determine Its Status in Turkey","Find HDV and Determine Its Status in Turkey \"SITU(HD)VATION\"","SITUHDVATION","Inclusion Criteria:\n\n* Adults (Age≥18)\n* Being HBsAg positive for at least six months\n* Being a citizen of the Republic of Türkiye\n\nExclusion Criteria:\n\n* There are no exclusion criteria in this study.",{"count":111,"type":21},20000,"13 Months","The aim of these study to determine the prevalence of hepatitis Delta virus (HDV) infections and the prognosis of HDV patients in Turkey's southeast. The investigators intend to arrange training sessions for 250 family physicians in Diyarbakir, Batman, Mardin, and Sanliurfa in order to determine those goals. The investigators will talk about diagnosing hepatitis B virus (HBV), HDV, hepatitis C virus (HCV), and Human Immunodeficiency virus (HIV) infections during these events. To ensure that patients with simultaneous HDV infection are evaluated for HIV\u002FHCV and to detect liver fibrosis with a non-invasive method.",[115,116,117,118,119],"Chronic Hepatitis D Infection","Fibrosis, Liver","Hepatocellular Carcinoma","Cirrhosis, Liver","Transmission Vertical",[121,117,122],"Chronic hepatitis D","Liver Cirrhosis","2024-08-08",{"date":125,"type":34},"2024-08-12",{"date":127,"type":34},"2024-03-11",{"date":129,"type":21},"2025-03-01",{"name":40,"class":41},2,""]